Ulys, L.L.C 13F annual report

Ulys, L.L.C is an investment fund managing more than $25.4 million ran by Raymond Debbane. There is currently 1 company in Mr. Debbane’s portfolio. The largest and only investment include Lexicon Pharmaceuticals Inc worth $25.4 million.

$25.4 million Assets Under Management (AUM)

As of 7th May 2021, Ulys, L.L.C’s top holding is 4,321,214 shares of Lexicon Pharmaceuticals Inc currently worth over $25.4 million and making up 100.0% of the portfolio value. Relative to the number of outstanding shares of Lexicon Pharmaceuticals Inc, Ulys, L.L.C owns more than approximately 0.1% of the company.

Currently, Ulys, L.L.C's portfolio is worth at least $25.4 million. The total portfolio value may be much higher due to cash assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.

Careers at Ulys, L.L.C

The Ulys, L.L.C office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Raymond Debbane serves as the Sole Member at Ulys, L.L.C.

One of the smallest hedge funds

The two most similar investment funds to Ulys, L.L.C are Btg Pactual Asset Management S.A.. Dtvm and Gavea Investimentos Ltda. They manage $25.4 million and $25.3 million respectively.

Raymond Debbane investment strategy

Ulys, L.L.C’s portfolio is diversified across 1 sector. Currently, their heaviest sector is Health Care — making up 100.0% of the total portfolio value. The fund focuses on investments in the United States as 100.0% of the portfolio companies are based in the United States.

The majority of the companies in the fund’s portfolio are large-cap stocks. Stocks with a size of more than $10 billion in market cap make up approximately 0.1% of the total holdings value. On the other hand, small-cap stocks make up only approximately 0.1% of the portfolio. The average market cap of the portfolio companies is close to $632 million.

The complete list of Ulys, L.L.C trades based on 13F SEC filings

These positions were updated on May 14th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.

Security	Shares Owned	Value	Allocation
Lexicon Pharmaceuticals Inc	No change 4,321,214	$25,366,000	100.00%
No transactions found
Showing first 500 out of 1 holdings